Rangering i aksjer
#29650
Medivir AB (publ) is a pharmaceutical company established in 1987 and... Medivir AB (publ) is a pharmaceutical company established in 1987 and headquartered in Huddinge, Sweden. It is dedicated to the research, development, and global commercialization of medicines, with a primary focus on oncology. The company currently markets Zoviduo (formerly Xerclear) for the treatment of labial herpes. Its robust development pipeline includes Remetinostat, targeting MF cutaneous T-cell lymphoma and basal cell carcinoma; MIV-818, aimed at liver cancer; and MIV-711, being advanced for osteoarthritis. Additionally, Medivir is progressing Birinapant and IGM-8444 for various solid tumor indications. Collaborative efforts are also key to its strategy, including a research partnership with SciLifeLab's Drug Discovery and Development Platform to discover antivirals for SARS CoV-2, alongside licensing agreements with Tango Therapeutics for a preclinical research program and with Ubiquigent Limited for the USP7 preclinical research program.
Aksjekurs
$0.68377137
Sist synkronisert: 2023-05-23
Handel Medivir AB (publ) (MVIR-B)
Pris MVIR-B pris med markedsverdi på B
Markedsverdi av Medivir AB (publ)(MVIR-B)
Markedsverdi: $20.23M
Per August 2026 har Medivir AB (publ) en markedsverdi på $20.23M. Dette gjør Medivir AB (publ) til det 29650th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Medivir AB (publ) fra 2000 til 2026
MVIR-B sammenlignet med topp 5 mest populære stocks
| Pris på MVIR-B |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.307T
|
+26,236,559.14%
|
|
|
|
|
$4.551T
|
+22,499,511.59%
|
|
|
|
|
$4.154T
|
+20,539,797.21%
|
|
|
|
|
$3.589T
|
+17,742,300.50%
|
|
|
|
|
$2.797T
|
+13,827,998.65%
|
